BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28509586)

  • 21. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin.
    Komeno Y; Kanda Y; Kandabashi K; Kawazu M; Goyama S; Takeshita M; Nannya Y; Niino M; Nakamoto T; Kurokawa M; Tsujino S; Ogawa S; Aoki K; Chiba S; Motokura T; Hirai H
    Am J Hematol; 2003 Mar; 72(3):220-2. PubMed ID: 12605397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.
    Niscola P; Tendas A; Cupelli L; Giovannini M; Piccioni D; Scaramucci L; Dentamaro T; Del Poeta G; de Fabritiis P
    Acta Haematol; 2015; 133(1):64-6. PubMed ID: 25139255
    [No Abstract]   [Full Text] [Related]  

  • 23. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation.
    Fuerst D; Mueller C; Beelen DW; Neuchel C; Tsamadou C; Schrezenmeier H; Mytilineos J
    Haematologica; 2016 Feb; 101(2):241-7. PubMed ID: 26611475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes.
    Krishnamurthy P; Potter VT; Barber LD; Kulasekararaj AG; Lim ZY; Pearce RM; de Lavallade H; Kenyon M; Ireland RM; Marsh JC; Devereux S; Pagliuca A; Mufti GJ
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):562-8. PubMed ID: 23266740
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of myeloablative allogeneic peripheral blood hematopoietic stem cell transplantation for refractory/relapsed AML patients in NR status.
    Liu N; Ning HM; Hu LD; Jiang M; Xu C; Hu JW; Wang J; Li YH; Li BT; Lou X; Yang F; Chen JL; Su YF; Li M; Wang HY; Ren J; Feng YQ; Zhang B; Wang DH; Chen H
    Leuk Res; 2015 Dec; 39(12):1375-81. PubMed ID: 26530539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia.
    Au WY; Chan AC; Lie AK; Chen FE; Liang R; Kwong YL
    Bone Marrow Transplant; 1998 Jan; 21(2):205-8. PubMed ID: 9489639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azacitidine effectively reduces
    Takei T; Yokoyama K; Shimizu E; Konuma T; Takahashi S; Yamaguchi R; Imoto S; Miyano S; Tojo A
    Leuk Lymphoma; 2018 Nov; 59(11):2755-2756. PubMed ID: 29648492
    [No Abstract]   [Full Text] [Related]  

  • 31. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.
    Mohty M; Malard F; Blaise D; Milpied N; Socié G; Huynh A; Reman O; Yakoub-Agha I; Furst S; Guillaume T; Tabrizi R; Vigouroux S; Peterlin P; El-Cheikh J; Moreau P; Labopin M; Chevallier P
    Haematologica; 2017 Jan; 102(1):184-191. PubMed ID: 27561720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m(2) intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia.
    Wanquet A; Crocchiolo R; Furst S; Granata A; Faucher C; Devillier R; Harbi S; Lemarie C; Calmels B; Vey N; Weiller PJ; Chabannon C; Castagna L; Blaise D; El-Cheikh J
    Leuk Lymphoma; 2016 Oct; 57(10):2315-20. PubMed ID: 26885686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia.
    de Witte T; Hermans J; van Biezen A; Vernant J; Kolb H; Zwaan F; Vossen J; Lönnqvist B; Beelen D; Ferrant A
    Bone Marrow Transplant; 1991; 7 Suppl 2():40. PubMed ID: 1878713
    [No Abstract]   [Full Text] [Related]  

  • 36. Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.
    Woehlecke C; Wittig S; Sanft J; Kreyenberg H; Gruhn B
    J Cancer Res Clin Oncol; 2015 Jul; 141(7):1283-90. PubMed ID: 25617314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy-related myelodysplastic syndrome presenting as isolated thrombocytopenia following chemotherapy for acute myeloid leukemia in a Chinese child.
    Guo L; Song H; Mao J; Tang Y
    Indian J Pediatr; 2014 Feb; 81(2):222-3. PubMed ID: 23824693
    [No Abstract]   [Full Text] [Related]  

  • 38. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
    Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor leukocyte infusion with graft-vs.-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Eur J Haematol; 2016 Mar; 96(3):297-308. PubMed ID: 26010204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.